市場調査レポート

商品コード

急性骨髄性白血病 (AML) 治療薬の世界市場：予測・動向

Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends

出版日: 2023年08月18日 | 発行: BCC Research

| ページ情報: 英文 122 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 5,500 862,180円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は、機能制限があるわけではありませんが、1回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 Users)

USD 6,600 1,034,616円

レポートPDFを同一国内の5名迄にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は計5回までとされます。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Site License)

USD 7,920 1,241,539円

レポートPDFを同一事業所に所属される方にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はありませんが、印刷したもののご利用はPDFのご利用者と同一範囲内です。

PDF (Enterprise License)

USD 9,504 1,489,847円

レポートPDFを同一企業の全ての事業所（資本100%子会社含む）にて人数に制限なく共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。印刷機能に回数制限はなく、同一企業内にて配布ご利用可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の急性骨髄性白血病 (AML) 治療薬の市場規模は、2023年の38億米ドルから、予測期間中は10.0%のCAGRで推移し、2028年には61億米ドルの規模に成長すると予測されています。

治療タイプ別で見ると、標的治療薬の部門が2023年の35億米ドルから、9.9%のCAGRで推移し、2028年には56億米ドルの規模に成長すると予測されています。また、アントラサイクリン系薬剤の部門は2023年の1億4,130万米ドルから、11.2％のCAGRで推移し、2028年には2億3,980万米ドルの規模に成長すると予測されています。

当レポートでは、世界の急性骨髄性白血病 (AML) 治療薬の市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、技術・特許動向、パイプラインの分析、ESGの展開、競合情勢、主要企業のプロファイルなどをまとめています。

List of Tables

Summary Table : Global Market for AML Treatments, by Drug Type, Through 2028
Table 1 : Global Population, Aged 60+, 2010-2050
Table 2 : North America, New Patents, 2023
Table 3 : AML Treatment: Targeted Therapy Drugs
Table 4 : AML Treatment Cost, by Country
Table 5 : AML Treatment-related Toxicities and Adverse Effects
Table 6 : Global COVID-19 Cases, 2023
Table 7 : Global Market for AML Treatments, by Region, Through 2028
Table 8 : North American Market for AML Treatments, by Country, Through 2028
Table 9 : European Market for AML Treatments, by Country, Through 2028
Table 10 : Asia-Pacific Market for AML Treatments, by Country, Through 2028
Table 11 : RoW Market for AML Treatments, Through 2028
Table 12 : Global AML, by Treatment Type, Targeted Therapy
Table 13 : Global Market for AML Treatments, by Targeted Therapy, Through 2028
Table 14 : Global Market for AML Treatments, by Anthracycline Drugs, Through 2028
Table 15 : Global Market for AML Treatments, by Other Chemotherapies, Through 2028
Table 16 : Global Market for AML Treatments, by IV Administration, Through 2028
Table 17 : Global AML IV Treatment
Table 18 : Global AML IV Treatment Cycle
Table 19 : Global Market for AML Treatments, by Oral Route Administration, Through 2028
Table 20 : Global AML, Oral Treatment
Table 21 : Global Market for AML Treatments, by Product, Through 2028
Table 22 : Global Market for AML Treatments, FLT3 Inhibitors, Through 2028
Table 23 : Global Market for AML Treatments, Apoptosis Stimulants, Through 2028
Table 24 : Global Market for AML Treatments, IDH Inhibitors, Through 2028
Table 25 : Global Market for AML Treatments, Angiogenesis Inhibitors, Through 2028
Table 26 : Global Market for AML Treatments, DNA Methylation Inhibitors, Through 2028
Table 27 : Global Market for AML Treatments, DNA Synthesis Inhibitors, Through 2028
Table 28 : Global Market for AML Treatments, DNA Intercalators, Through 2028
Table 29 : ESG Framework for the Global Pharmaceutical Industry
Table 30 : Social Framework, Global Pharmaceutical Industry
Table 31 : Top Pharma Companies, ESG Ratings
Table 32 : Global Market for AML Treatments, New Technologies
Table 33 : Global AML Treatments, by Company Market Share, 2022
Table 34 : Global AML Treatments, by Product Share, 2022
Table 35 : Global AML Treatments, by Product Sales, 2022
Table 36 : Global AML Treatments, Company Information
Table 37 : Global AML Treatments, Key Financials, 2022
Table 38 : Patents on AML Drugs, 2018-Present
Table 39 : Selected Manufacturer Patents on AML Drugs, 2018-Present
Table 40 : Patents on FLT3 Inhibitors, 2018-Present
Table 41 : Selected Manufacturer Patents on FLT3 Inhibitors, 2018-Present
Table 42 : Patents on Apoptosis Stimulants, 2018-Present
Table 43 : Selected Manufacturer Patents on Apoptosis Stimulants, 2018-Present
Table 44 : Patents on IDH Inhibitors, 2018-Present
Table 45 : Selected Manufacturer Patents on IDH Inhibitors, 2018-Present
Table 46 : Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
Table 47 : Selected Manufacturer Patents on Anaplastic Lymphoma Kinase Inhibitors, 2018-Present
Table 48 : Patents on DNA Methylation Inhibitor, 2018-Present
Table 49 : Selected Manufacturer Patents on DNA Methylation Inhibitor, 2018-Present
Table 50 : Selected Apoptosis Stimulants in Clinical Trials, 2023
Table 51 : Selected IDH Inhibitors in Clinical Trials, 2023
Table 52 : Selected IDH Inhibitors in Clinical Trials, 2023
Table 53 : Selected DNA Methylation Inhibitors in Clinical Trials, 2023.
Table 54 : Selected FLT3 Inhibitors in Clinical Trials, 2023
Table 55 : Selected DNA Synthesis Inhibitors in Clinical Trials, 2023
Table 56 : Global AML Treatment Market: Mergers and Acquisitions, 2019-2022
Table 57 : AbbVie: Product Information
Table 58 : AbbVie: Revenue, 2020-2022
Table 59 : AbbVie: Recent Key Developments
Table 60 : Amgen: Revenue, 2020-2022
Table 61 : Amgen: Key Developments, 2021 and 2022
Table 62 : Astellas Pharma: Revenue, 2020-2022
Table 63 : Astellas Pharma: Recent Key Developments
Table 64 : Bayer AG: Marketed Products
Table 65 : Bayer AG: Annual Revenue, 2020-2022
Table 66 : Bayer AG: Key Developments, 2022 and 2023
Table 67 : Biogen: Annual Revenue, 2020-2022
Table 68 : Biogen: Key Developments, 2018-2023
Table 69 : Bristol-Myers Squibb: Product Information
Table 70 : Bristol-Myers Squibb: Revenue, 2020-2022
Table 71 : Bristol-Myers Squibb: Key Developments, 2020 and 2021
Table 72 : Daiichi Sankyo: Product Information
Table 73 : Daiichi Sankyo: Annual Revenue, 2020-2022
Table 74 : Daiichi Sankyo: Key Developments, 2022 and 2023
Table 75 : Gilead Sciences: Annual Revenue, 2020-2022
Table 76 : Gilead Sciences: Key Developments, 2022 and 2023
Table 77 : GlaxoSmithKline PLC: Product Segment
Table 78 : GlaxoSmithKline PLC: Annual Revenue, 2020-2022
Table 79 : GlaxoSmithKline PLC: Recent Developments, 2022
Table 80 : Merck & Co. Inc.: Business Segment
Table 81 : Merck & Co. Inc.: Annual Revenue, 2020-2022
Table 82 : Merck & Co. Inc.: Key Developments, 2022
Table 83 : Novartis: Product Information
Table 84 : Novartis: Revenue, 2020-2022
Table 85 : Novartis: Key Developments
Table 86 : Pfizer Inc.: Product Segments
Table 87 : Pfizer Inc.: Annual Revenue, 2020-2022
Table 88 : Pfizer Inc.: Top Brands, 2022
Table 89 : Pfizer Inc.: Key Developments, 2019-2023
Table 90 : Sanofi: Business Segment
Table 91 : Sanofi: Annual Revenue, 2020-2022
Table 92 : Sanofi: Key Developments, 2021-2023
Table 93 : Servier: Product Information
Table 94 : Servier: Annual Revenue, 2020-2022
Table 95 : Servier: Key Developments, 2022 and 2023
Table 96 : Teva: Financials, 2020-2022
Table 97 : Teva: Key Developments, 2021-2023
Table 98 : Acronyms Used in This Report

List of Figures

Summary Figure A : Global Market for AML Treatments, by Drug Type, 2020-2028
Summary Figure B : Global Market Shares of AML Treatments, by Drug Type, 2022
Figure 1 : Global Market Shares of AML Treatments, by Region, 2022
Figure 2 : North American Market Shares of AML Treatments, by Country, 2022
Figure 3 : European Market Shares of AML Treatments, by Country, 2022
Figure 4 : Asia-Pacific Market Shares of AML Treatments, by Country, 2022
Figure 5 : Global AML Treatment Market Shares, by Drug Type, 2022
Figure 6 : Global Market Shares of AML Treatments, by Route of Administration, 2022
Figure 7 : Global Market Shares of AML Treatments, by Oral Route Administration, 2022
Figure 8 : Global Market Shares of AML Treatments, by Product, Through 2028
Figure 9 : Global Electricity from Renewable Sources, 2017-2021
Figure 10 : Global Recycled Waste, 2017-2021
Figure 11 : Global CO₂ Emissions, 2017-2021
Figure 12 : Global AML Treatments, by Company Market Share, 2022
Figure 13 : Global AML Treatments, by Product Sales, 2022
Figure 14 : AbbVie: Market Share, by Country, 2022
Figure 15 : Bristol-Myers Squibb: Revenue Share, by Country, 2022
Figure 16 : Daiichi Sankyo: Market Share, by Region/Country, 2022
Figure 17 : Gilead Sciences: Revenue, by Product, 2022
Figure 18 : GlaxoSmithKline PLC: Annual Revenue, by Segment, 2020-2022
Figure 19 : Merck & Co. Inc.: Annual Revenue, by Segment, 2020-2022
Figure 20 : Novartis Innovative Medicine: Market Share, by Region/Country, 2022
Figure 21 : Novartis Sandoz: Market Share, by Region/Country, 2022
Figure 22 : Sanofi: Revenue, by Region/Country, 2022
Figure 23 : Sanofi: Revenue, by Segment, 2022
Figure 24 : Teva: Market Share, by Region, 2022

Product Code: PHM276A

Highlights:

The global acute myeloid leukemia (AML) treatments market should reach $6.1 billion by 2028 from $3.8 billion in 2023 at a compound annual growth rate (CAGR) of 10.0% for the forecast period of 2023 to 2028.

Targeted therapy segment of the global AML treatments market is expected to grow from $3.5 billion in 2023 to $5.6 billion in 2028 at a CAGR of 9.9% for the forecast period of 2023 to 2028.

Anthracycline drugs segment of the global AML treatments market is expected to grow from $141.3 million in 2023 to $239.8 million in 2028 at a CAGR of 11.2% for the forecast period of 2023 to 2028.

Report Scope:

This report aims to comprehensively study the market size of AML and treatments for a global market. Current and historical market revenues can be estimated based on treatment type, route of administration, end use, distribution channel and region.

Report Includes:

42 data tables and 57 additional tables
An overview of the global market for acute myeloid leukemia (AML) treatment
Analyses of global market trends, with data from 2020 to 2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
Highlights of the market potential and characterization of AML market based on treatment type, route of administration type, end-users, distribution channel, region
Coverage of various risk factors associated with AML, such as exposure to radiation or chemicals, genetic disorders, and weakened immune system
Description of major treatment options for AML such as, chemotherapy, targeted therapy, and stem cell transplantation
Information on recent mergers, acquisitions, collaborations, agreements, partnerships, product launches, and expansions in the market and a relevant patent analysis
Detailed company profiles of major players in the market of the industry, including AbbVie, Daiichi Sankyo, GlaxoSmithKline PLC, Pfizer Inc. and Servier

Chapter 1 Introduction

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown

Chapter 2 Summary and Highlights

Market Outlook
This Report Highlights

Chapter 3 Market Overview and Definitions

Overview
Acute Myeloid Leukemia
The Global Regulatory Structure for AML
Pricing and Reimbursement for AML
Therapies/Drugs to Treat AML
FLT3 Inhibitors
IDH Inhibitors
Apoptosis Stimulants
DNA Methylation Inhibitors
DNA Intercalators
Angiogenesis Inhibitors
DNA Synthesis Inhibitors

Chapter 4 Market Dynamics

Market Drivers
Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Molecular Diagnostics
Minimal Residual Disease (MRD) Monitoring
Gene Expression Profiling
Fusion Gene Detection
Liquid Biopsies
R&D
Regulatory Environment
Personalized Medicine
Collaborative Efforts
Patient Advocacy and Awareness
Market Opportunity
Strategic Initiative
Market Restraints
High Costs
Limited Treatment Options
Treatment-related Toxicity and Adverse Effects
Regulatory and Reimbursement Challenges

Chapter 5 Impact of COVID-19

Introduction
COVID-19 Impact on AML Treatments

Chapter 6 Market Breakdown by Region

Market Overview and Discussion
North America
Europe
Asia-Pacific
Rest of the World

Chapter 7 Market Breakdown by Treatment Type

Market Overview and Discussion
Targeted Therapy
Anthracycline Drugs
Other Chemotherapies
Targeted Therapy
Anthracycline Drugs
Other Chemotherapies

Chapter 8 Market Breakdown by Route of Administration

Market Overview and Discussion
Intravenous (IV) Administration
Oral Administration
Intravenous (IV) Administration

Chapter 9 Market Breakdown by Product

FLT3 Inhibitors
Apoptosis Stimulants
Angiogenesis Inhibitors
DNA Methylation Inhibitors
DNA Synthesis Inhibitors
DNA Intercalators

Chapter 10 ESG Development

Introduction
Environment
Governance

Chapter 11 Emerging Trends and Technologies

Introduction

Chapter 12 Competitive Landscape

Overview
Industry Scenario
Company Shares

Chapter 13 Patent Analysis

Patent Analysis by Manufacturer

Chapter 14 Pipeline Analysis

Clinical Trail Scenario

Chapter 15 M&A and Venture Funding Outlook

Introduction

Chapter 16 Company Profiles

ABBVIE
AMGEN INC.
ASTELLAS PHARMA INC.
BAYER AG
BIOGEN
BRISTOL MYERS SQUIBB
DAIICHI SANKYO CO. LTD.
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.

急性骨髄性白血病 (AML) 治療薬の世界市場：予測・動向

Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends

目次

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場概要と定義

第4章 市場力学

第5章 COVID-19の影響

第6章 市場内訳：地域別

第7章 市場内訳：治療タイプ別

第8章 市場内訳：投与経路別

第9章 市場内訳：製品別

第10章 ESGの展開

第11章 新しい動向・技術

第12章 競合情勢

第13章 特許分析

第14章 パイプライン分析

第15章 M&Aとベンチャー資金調達の見通し

第16章 企業プロファイル

第17章 付録：頭字語

List of Tables

List of Figures

Highlights:

Report Scope:

Report Includes:

Table of Contents

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview and Definitions

Chapter 4 Market Dynamics

Chapter 5 Impact of COVID-19

Chapter 6 Market Breakdown by Region

Chapter 7 Market Breakdown by Treatment Type

Chapter 8 Market Breakdown by Route of Administration

Chapter 9 Market Breakdown by Product

Chapter 10 ESG Development

Chapter 11 Emerging Trends and Technologies

Chapter 12 Competitive Landscape

Chapter 13 Patent Analysis

Chapter 14 Pipeline Analysis

Chapter 15 M&A and Venture Funding Outlook

Chapter 16 Company Profiles

Chapter 17 Appendix: Acronyms

第1章イントロダクション

第2章サマリー・ハイライト

第3章市場概要と定義

第4章市場力学

第6章市場内訳：地域別

第7章市場内訳：治療タイプ別

第8章市場内訳：投与経路別

第9章市場内訳：製品別

第11章新しい動向・技術

第12章競合情勢

第13章特許分析

第14章パイプライン分析

第16章企業プロファイル

第17章付録：頭字語